Acute Encephalopathies and Psychiatry by Karim Sedky et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
6 
Acute Encephalopathies and Psychiatry 
Karim Sedky1, Racha Nazir1 and Steven Lippmann2 
1Penn State College of Medicine, Hershey, PA 
2University of Louisville School of Medicine, Louisville, KY 
USA 
1. Introduction 
An encephalopathic delirium occurs due to a disturbance of brain function leading to a 
change in mental status. Fluctuating consciousness, hallucinations, disorientation, and 
short-term memory deficits are common presentations. This syndrome is more frequent 
among elderly people and occurs in up to 30% of hospitalized patients1. There are many 
medical conditions that can cause a delirium, including organ failures and electrolyte 
imbalances, etc. Polypharmacy and/or toxicities increase the risk of developing a 
confusional state. When considering a delirium diagnosis, a thorough evaluation is 
mandatory. This includes history taking from patients and their family, a physical 
examination, and a neurological evaluation. Laboratory investigations include a basic 
metabolic panel, a complete blood count, liver function tests, a calcium assay, toxicology 
or plasma drug level screening, thyroid stimulating hormone, urine analysis, and in 
certain cases, a rapid plasma reagin (RPR) and/or human immunodeficiency viral levels 
(HIV), etc. A computerized tomography scan of the head or magnetic resonance imaging 
is obtained in most cases. Early, prompt management of delirium decreases morbidity 
and mortality.  
Patients suffering from certain psychiatric conditions can be misdiagnosed as having an 
encephalopathy and vice versa. Psychosis is common in many psychiatric disorders and 
may include auditory hallucinations. Psychoses in confusional states will prompt the 
search for medical causes. Visual hallucinations are most typically observed in cases of a 
delirium due to a medical condition (e.g., electrolyte imbalance, brain tumor, toxicities, 
and/or seizures, etc). Tactile hallucinations, or formications, are a feeling that bugs are 
crawling under the skin and are common with drug use (e.g., cocaine) or alcohol 
withdrawal. Olfactory hallucinations are often noted in individuals suffering from 
seizures or brain disorders. Delirium diagnosis becomes especially challenging in people 
with history of a psychiatric disorder presenting with a new change in mental status. It is 
important for physicians to be aware of such disorders and to quickly recognize adverse-
events caused by psychotropic medications and/or the occurrence of new onset medical 
disorders. Diagnosis is especially difficult in chronically ill patients, who are poor 
historians with inability to communicate coherently. This chapter reviews causes of 
delirium that are secondary to psychiatric drugs as well as reviewing psychiatric 
mimickers of delirium.  
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2. Encephalopathy secondary to psychiatric treatments 
There are a vast variety of psychiatric medications available. These include antidepressant 
drug, anxiolytic agents, antipsychotic medications, and mood stabilizers (e.g., antiepileptic 
pharmacueticals and/or lithium). Through different mechanisms of action, these 
medications can result in causing an acute or chronic encephalopathy. Older versions of the 
psychopharmaceuticals are the most common offending agents. For example, tricyclic 
antidepressant drugs are more likely to cause anticholinergic induced delirium as compared 
to the selective serotonin reuptake inhibitors. Neuroleptic malignant syndrome occurs with 
higher frequency when utilizing older neuroleptic medications versus experience with the 
newer generation of antipsychotic agents. 
2.1 Medications with anticholinergic effects 
There are multiple medications that induce anticholinergic effects that include cognitive 
dysfunction, decreased concentration, confusion, and memory deficits2 (see Table-1). 
Delirium occur especially in elderly persons secondary to anticholinergic side-effects caused 
by antipsychotic and antidepressant medications. A survey of elderly patients hospitalized 
with an acute medical illness revealed that a significant number were prescribed 
antipsychotic agents and experienced a delirium, as compared to those not receiving them 
(10% versus 0%)3.  
Many tricyclic and tetracyclic antidepressant medicines are high in anticholinergic potential. 
Amitriptyline, protriptyline, doxepin, imipramine, and trimipramine are the most notable. 
In one study, such antidepressant agents were responsible for causing an acute delirium in 
13.6% of patients4. The second generation antidepressant medications usually have less 
anticholinergic side-effects5. 
Clozapine, chlorpromazine, and thioridazine are the antipsychotic agents that have the most 
anticholinergic potential for causing a delirium6. Olanzapine has a moderate affinity to this 
receptor7; other antipsychotic drugs are less likely to cause encephalopathy due to 
anticholinergia.  
First generation antipsychotic agents and risperidone often can result in parkinsonian signs 
and symptoms that include resting tremors, shuffling gait, a flat affect, cog-wheel muscular 
rigidity, and bradykinesia. Benzotropine and trihexyphenidyl are frequently co-utilized to 
medicate this adversity, but particularly in elderly patients adding these medicines can 
induce a delirium. 
2.2 Neuroleptic Malignant Syndrome (NMS) 
Antipsychotic medications are prescribed to treat people with psychotic disorders and acute 
agitation. Haloperidol is frequently used in acute medical settings due to its low 
anticholinergic effects and wide availability in oral and parenteral forms. Delirium can 
signify the induction of neuroleptic malignant syndrome by antipsychotic drugs. Other 
medications with similar properties include metoclopramide and prochlorperazine. 
Dopamine receptor blockade is hypothesized as the pathology behind NMS, but other 
etiologies might include sympathetic or adrenal dysregulation. Sudden discontinuation of 
dopaminergic agonists like bromocriptine can also lead to a similar condition. 
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ANTIDEPRESSANT 
DRUGS 
SSRIs 
fluoxetine, paroxetine, 
fluvoxamine, sertraline, 
citalopram, & 
escitalopram 
 
Bupropion 
 
SNRIs  
nefazdone, venlafaxine, 
desvenlafaxine, & 
duloxetine 
 
TCAs  
(tri- & tetracyclic 
antidepressants) 
amitriptyline 
trimipramine 
doxepine 
clomipramine 
imipramine 
desipramine 
nortriptyline 
 
MAOIs 
phenelzine 
tranylcypromine 
isocarboxazid 
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mesoridazine 
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NEUROLEPTICS  
haloperidol 
perphenazine 
fluphenazine 
loxapine 
thiothixene 
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risperidone 
paliperidone 
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SSRI: Selective Serotonin Reuptake Inhibitor; SNRI: Selective Norepinephrine Reuptake Inhibitor; TCA: 
Tri- and Tetracyclic Antidepressant; MAOI: Monoamine Oxidase Inhibitor. 
Table 1. Anticholinergic Effects of Psychotropic Medications 
Neuroleptic malignant syndrome occurs in up to 0.02% of individuals medicated with 
antipsychotic agents8. It was previously thought to be of a higher incidence; however, early 
detection, cautious neuroleptic dosing, and the introduction of second generation 
antipsychotic medicines might have contributed to this decrease in frequency. NMS is more 
common in people with dehydration, agitation, iron deficiency, and in rapid antipsychotic 
medication increases or high dosage applications. Risk may increase also when 
antipsychotic medicines are co-prescribed with lithium and in patients with a history of 
NMS. The onset can be within a week of medication initiation8. 
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Autonomic dysfunction is a prominent part of the presentation. Confusion and muscle 
stiffness are noted. Laboratory findings include elevated transaminases, aldolase, lactic acid 
dehydrogenase, leucocytosis, and/or metabolic acidosis. High creatinin phosphokinase 
induced by rhabdomyolysis might result in kidney failure. 
Differentiate this syndrome from central nervous system infections which are associated 
with headaches, fever and localizing signs. Heatstroke can also present with hyperthermia, 
tachycardia, and confusion; yet, it is differentiated by findings of dry skin and hypotonia. 
Serotonin syndrome is related to taking serotonergic agents and evidences muscle tremors 
rather than stiffness. Malignant hyperthermia is a reaction to anesthetic agents. In the 
workup always rule out psychiatric cases of malignant catatonia.  
NMS varies from a life-threatening situation to a self-limited condition, with 63% of cases 
taken off of the drug recovering within several days8. Parenteral depot medication exposure 
greatly prolongs the course. Fatalities are observed in up to 10% of patients. Immediate 
discontinuation of the antipsychotic drug is essential.  
2.3 Sedative-hypnotic agents 
Benzodiazepines and barbiturates can precipitate delirium. Up to 13.9% of patients 
presenting with acute encephalopathy due to medication, were caused by benzodiazepine 
intake6. In elderly individuals and/or those with liver disease, medication levels can quickly 
become toxic causing an encephalopathy, even at normal medication dosages. The longer 
acting benzodiazepines might have a higher risk of causing delirium as compared to shorter 
acting variants (relative ratio was 5.4 versus 2.6)9. Higher dosages are also more likely to 
cause an encephalopathy than lower ones (relative ratio was 3.3 versus 2.6).  
Benzodiazepines are usually indicated as a short-term treatment for anxiety, insomnia, and 
alcohol withdrawal. Yet, very often these medicines are utilized over the long-term. After 
prolonged duration use or abuse, sudden dosage taper or discontinuation can lead to severe 
withdrawal symptoms including convulsions and an encephalopathy. Deaths from 
benzodiazepine withdrawal occur. Thus, seizure precautions and prompt replacement of the 
sedative medication is emergently required at dosages that stop seizures and suppress 
hyperadrenergic withdrawal signs10. 
Barbiturates are no longer commonly utilized; they are mainly prescribed to treat seizure 
disorders or alcohol withdrawal delirium, especially since some of them have a long half-life 
and are inexpensive. Sedative toxicity with psychosis has been reported particularly during 
medication overdoses. Withdrawal delirium (i.e., delirium tremens) can occur after sudden 
decreases or discontinuation of barbiturates. Isolated visual hallucinations, without overt 
toxicity or withdrawal, are reported in adults and children11. 
2.4 Serotonin syndrome 
Serotonin syndrome occurs due to hyperstimulation of the 5-HT1A receptors12. Etiologies 
include taking serotonin precursors or agonists (e.g., buspirone and trazodone), 
neurotransmitter releasers (e.g., amphetamines), reduced serotonin-reuptake from selective 
serotonin reuptake inhibitor (SSRI) drugs and related agents, or diminishing serotonin 
metabolism by taking monoamine oxidase inhibitors (MAOIs). Co-prescribing serotonergic 
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medicines, as in MAOIs with SSRIs or sumatriptan and related drugs, must be avoided. 
Drug interaction through inhibitors of cytochrome P450 can lead to inhibition of hepatic 
degradation of the SSRIs, leading to a high blood levels and toxicity risk13.  
Serotonin syndrome is an uncommon side-effect of antidepressant drugs, but it is more 
likely once utilizing medications with a long half-life (e.g., flouxetine). This adversity 
usually occurs within the first few days of medication initiation13. Three different levels of 
the disorder are described13: 1. a mild form with tremors, myoclonus, diaphoresis, and 
restlessness; 2. a syndrome of impaired consciousness or coma, neurological features of 
myoclonus, tremors or rigidity, autonomic hyperactivity, or breathing difficulties; and 3. a 
dangerous, toxic condition with coma, seizures, and fever. Deaths occur in the more severe 
versions, with brain edema and a coagulopathy. Laboratory findings include elevation of 
the creatinin kinase, transaminases, and leukocytosis. 
2.5 Lithium 
Lithium is a salt frequently used to treat bipolar disorders or as an augmenting agent for 
those who suffer from depression. It is effective for controlling manic symptoms at blood 
levels of 0.6 to 1.2 μg/ml and for maintenance therapy at 0.3 to 0.6 μg/dl. Lithium toxicity is 
common in dehydrated individuals (see Table-2). Nephrogenic diabetes insipidus occurs in 
10% of treated patients and causes dehydration, possibly precipitating toxicity and an 
encephalopathy. For people over 65 years-of-age, with impaired renal function and 
polypharmacy, the risk for this adversity increases by two-fold14,15. When co-prescribed with 
diuretics (e.g., hydrochlorthiazide), non-steriodal anti-inflammatory drugs (e.g., ibuprofen), 
and/or angiotensin converting enzyme inhibitors (e.g., captopril), lithium excretion is 
reduced leading to potential toxicity if dose adjustment is not made15.  
Toxic symptoms are generally correlated to serum blood lithium levels. Mild cases occur 
when concentrations are between 1.5 to 2μg/ml, presenting with gastrointestinal upset, 
mild tremors, and weakness. With moderate toxicity, concentrations range from 2 to 
2.5μg/ml and complaints include tinnitus, muscle twitches, dysarthria, and hyperreflexia 
manifest. At higher blood levels, severe toxicity includes delirium, seizures, coma, and even 
death; in these cases, blood concentrations are less well correlated to clinical status. 
Neurotoxicity with permanent sequellae follows high level intoxication15. Thus, significant 
toxicity mandates hydration and immediate discontinuation of lithium; hemodialysis maybe 
required.  
[1] Dehydration 
a. Increased perspiration 
b. Nephrogenic diabetes insipidus 
[2] Impaired renal function-nephritis or renal tubular nephrosis 
[3] Medications 
a. Loop diuretics e.g., hydrochlorothiazide 
b. Angiotensin converting enzyme inhibitor e.g., captopril 
c. Non-steroidal anti-inflammatory drugs e.g., ibuprofen 
Table 2. Causes of Lithium Toxicity 
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There is controversy about the safety of combing lithium with antipsychotic medications; 
several sporadic cases of encephalopathy have been reported with such combinations16. This 
might be explained by lithium enhancing dopamine receptor blockade17. Otherwise, co-
prescribing leads to a higher concentration of intracellular lithium, in a dose-dependent 
nature16. One retrospective study documented low encephalopathy rates18. Nevertheless, 
such combinations remain frequently utilized, effective, and safe. 
2.6 Medication causing hepatotoxicity 
Many psychopharmaceuticals can cause liver damage (see Table-3). Acute hepatic failure is 
an idiosyncratic reaction to medications and can lead to encephalopathy within weeks of 
first symptom development. Chronic hepatotoxicity and fibrosis usually occurs with long-
term treatment; delirium occurs later in the disease process.  
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Atomoxetine 
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SSRI: Selective Serotonin Reuptake Inhibitor; SNRI: Selective Norepinephrine Reuptake Inhibitor; 
MAOI: Monoamine Oxidase Inhibitor. 
Table 3. Psychiatric Medications and Hepatotoxicity 
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A prominent example was the selective serotonin-norepinephrine reuptake inhibitor, 
nefazdone, and it has been withdrawn from the market due to this problem. Other drugs 
can also result in hepatotoxicity; pemoline and tacrine are major offending agents and are 
rarely utilized now due to this adverse-event. Antiepileptic/mood stabilizer medicines, too, 
sometimes can induce liver dysfunction19. Carbamazepine and valproate products, like 
divalproex, may cause hepatic inflammation and an encephalopathy. Hyperammonemia 
might develop even in the absence of other abnormal liver function tests20. 
2.7 Electrolyte abnormalities 
Several psychotropic medications may lead to hyponatremia, including antidepressant and 
antiepileptic/mood stabilizer drugs. Carbamazepine is a well-established offender. 
Although the mechanism is unknown, stimulation of the 5-HT2 and 5-HT1c might lead to 
increased release of antidiuretic hormone (ADH) and water retention at renal tubules21. 
Inhibition of norepinephrine reuptake can also lead to increased ADH through α1-
adrenergic receptor stimulation21.  
People with serum sodium concentrations at 125-130 mEq/l would present with 
gastrointestinal complaints of nausea and vomiting and the neurological symptoms of 
fatigue, headaches, and muscle cramps. Delirium ensues with levels below 125mEq/l22. At 
concentrations lower than 120 mEq/l, convulsions, respiratory failure, and death are 
reported21. However, some individuals with chronic hyponatremia might be asymptomatic 
even at more severely low sodium levels. Laboratory evidence includes lower than normal 
serum osmolality and increased urine sodium or osmolality21.  
Hyponatremia can occur just weeks after medication initiation21. Selective serotonin 
reuptake inhibitors may have a greater potential for causing this side-effect compared to 
other antidepressant drugs (ranging from 0.5-32%)21,22. Patients older than age 65 carry a six-
fold increased risk. Female gender, high medication doses, low baseline sodium levels, 
being underweight, co-treatment with diuretic agents, and smoking tobacco are other risk 
factors (nicotine stimulates vasopressin causing enhancement of water reabsorption from 
renal tubules)22. 
2.8 Leucopenia, neutropenia and/or agranulocytosis 
It is important to note that psychotropic medications have been attributed to leucopenia and 
in rare cases neutropenia23. This can predispose people to infections, septicemia, delirium, 
and death. Clozapine is the antipsychotic drug most associated with bone marrow 
suppression and use requires special registry for patients and their physicians. A complete 
blood cell count with white cell differentials is indicated weekly following drug initiation in 
the first few weeks; the frequency then can be decreased to every other week. Since 
agranulocytosis develops usually in the first 18 months of this pharmacotherapy, frequency 
of blood counts can be decreased to monthly intervals after six months of stability. 
Nevertheless, bone marrow suppression has been reported years after uncomplicated 
therpy24. Immediate medication discontinuation is mandated in all cases of agranulocytosis. 
Antiepileptic drugs also have a risk of causing bone marrow suppression. This is especially 
true with carbamazepine and valproate products. Other medications only rarely cause this 
side-effect. In contrast, lithium may induce leucocytosis. 
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2.9 Electroconvulsive Therapy (ECT) 
Electroconvulsive therapy is frequently used to treat patient suffering from depression. 
Delirium can result from the pre-treatment anesthesia or due to the ECT itself. An ECT-
induced delirium occurs in up to 12% of individuals, usually resolving spontaneously 
within an hour25. Assurance and benzodiazepines are used to treat any associated agitation. 
Older age, comorbid neurological disorders, and rapid discontinuation of benzodiazepines 
after long-term treatment during an ECT series increases the incidence of delirium. Since 
continued seizures leading to status epilepticus should be ruled out, many physicians 
continue electroencephalographic monitoring in the post-convulsive period to detect such 
ictus. A higher incidence of confusion might follow co-prescribing lithium or dopaminergic 
agents during ECT. 
3. Psychiatric disorders mimicking encephalopathy 
3.1 Schizophrenia and schizoaffective disorder  
Schizophrenia occurs in up to 1% of the population and usually presents first in the late 
teens and early twenties. According to the Diagnostic and Statistical Manual for Mental 
Disorders-fourth edition-revised (DSM-IV-R) criteria, to fit this diagnosis, the individual has 
to have at least two major symptoms for at least six months26: delusions which are false 
fixed beliefs, hallucinations which are misperception of stimuli by the five senses in the 
absence of stimulation, disorganization of speech, behavior, and/or thought disorder, 
catatonia or negative symptoms. The negative symptom profile includes apathy, slow 
movements, ambivalence, and a blunted affect. Catatonia includes motor hyperactivity or 
excitability, negativism, mutism, waxy flexibility of limbs, and echolalia or echopraxia27.  
Only one presenting symptom might be enough to diagnose this disorder if there are at least 
two voices talking to each other in the patient’s mind, "commentary voices", and/or if the 
delusion is bizarre. This is particularly so when premorbid social dysfunction has long 
proceeded the acute psychotic episode, with compromised interpersonal relationships, 
oddities in behaviors, and low school performance. 
There are five sub-types of schizophrenia. This includes a catatonic type; a disorganized 
version with disorganization of speech, behavior, or thought process; a paranoid type with 
delusions; an undifferentiated form which has a mixture of symptoms; and a residual one 
which is less specific but more chronic. Patients presenting with catatonia or disorganization 
are the ones most easily misdiagnosed. 
History taking, with collateral information from the families helps to differentiate 
schizophrenia from an encephalopathy. A long history of mental illness and its onset 
during teenage years are usually prominent in schizophrenia; this psychiatric illness has 
little variation within the day, is characterized by psychotic relapse, and generally 
evidences intact cognition. Delirium waxes and wanes over time and evidences confusion, 
poor memory, and disorientation. Preserved cognition is the best clue to ruling out a 
delirium. Visual hallucinations occur during delirium, while auditory hallucinations more 
common to schizophrenia. Schizoaffective disorder is a psychosis with a mood disorder 
component.  
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3.2 Depressive disorder and bipolar spectrum 
Major depressive disorder affects up to 20% of the population, with a higher prevalence 
among females. Symptoms include feeling sad or irritable, decrease in energy and interest, 
change in appetite and weight, sleep problems, guilt, anhedonia, and thoughts of suicide. 
Four to five symptoms are required for at least a duration of two weeks. This syndrome can 
be associated with psychoses, disorganization, and/or catatonia. Delusions are usually 
related to one theme and can include nihilistic themes (e.g., the world is coming to an end) 
and Cotard syndrome (i.e., feeling one is dead and internal organs are decaying). Thorough 
history gathering and clinical evaluation usually aids in diagnosis. Antidepressant 
medication alone may not be adequate in psychotic cases, when the addition of an 
antipsychotic drug is indicated. Since this syndrome is frequently associated with 
suicidality, medication overdoses should be considered, especially when confusion or a 
change of mental status is observed. In cases presenting with tricyclic or tetracyclic 
antidepressant overdose, cardiac monitoring is mandated. Frequent blood work is required 
for patients on polypharmacy or clozapine. Liver function monitoring is essential in persons 
medicated with antiepileptic/mood stabilizer drugs. 
Bipolar Disorders occur at a rate of 1% in the general population. This cyclic ailment 
alternates between depression and mania/hypomania, which is characterized by elated or 
irritable mood, decreased need for sleep, grandiosity, pressured speech, risk taking 
behaviors, impulsivity, flight of ideas or racing thoughts, and/or distractibility. Three or 
four symptoms are needed to confirm this diagnosis. Psychoses can also be observed. 
“Delirious mania” has been described in individuals presenting initially with grandiosity, 
excitement, and psychosis. They are disorganized and can become delirious. Such cases 
have been described frequently in younger populations with catatonia evident28. This can be 
challenging to differentiate from delirium alone, especially in elderly cases. History taking, 
physical examination, and laboratory investigations are important to reach a sound 
diagnosis. This illness is characterized by acute onset, history of an affective disorder, 
mania, and response to bipolar treatment. Overt delirium cases evidence cognitive 
abnormalities, such as disorientation, and require a medical evaluation to rule out toxicities, 
electrolyte abnormalities, or organ failures, etc. 
3.3 Dementia 
This disorder is more common in elderly patients and increases in frequency as the 
individual ages. It can be multifactorial and includes Alzheimer disease, Lewy body 
dementia, vascular causes, vitamin deficiency, or even infectious offenders (e.g., syphilis). 
Individuals or relatives usually complain of gradual memory deterioration, aphasia 
(impairment in language or speech), apraxia (inability to perform complex movements in 
presence of normal motor function), and problems with executive function. Dementia has a 
more constant memory deficit pattern, without a waxing and weaning course. Aside from 
Lewy body dementia, in which visual hallucinations are common, hallucinations usually 
occur late in the disease or when comorbid delirium exists. Treatable etiologies such as 
vitamin deficiency, infectious etiologies, and vascular disease should be detected and 
promptly managed to prevent irreversible disease progression. 
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3.4 Alcohol and substance-induced delirium 
The American Psychiatric Association manual, the DSM-IV-R, has standardized psychiatric 
disorders that include delirium due to drugs or alcohol. Encephalopathies can occur in 
individuals consuming alcohol during two stages: 1. alcohol intoxication with delirium and 
2. alcohol withdrawal delirium. There is also an alcohol-induced, persisting amnestic 
disorder with residual dementia that presents initially in a delirium (with Wernicke’s 
Korsakoff syndrome). Amphetamine, cannabis, cocaine, hallucinogen, inhalant, opioid, and 
phencyclidine (PCP) drugs can be related to a delirium. Other substances are associated 
with disorientation and are categorized under a substance-induced delirium group [e.g., 
gamma hydroxybutyrate (GHB)]. 
3.4.1 Alcohol withdrawal / delirium tremens 
Alcohol is a very frequently abused substance. A single 12-ounce drink of beer, 4-ounces of 
wines, or a 1-1.5 ounces of 80-proof of spirits raises the blood alcohol level by 15-20mg/dl, 
in a 150-pound normal male29. It takes 30-90 minutes to reach a peak concentration and in 
healthy people, a further hour to be metabolized29. Detoxification is dependent on alcohol 
dehydrogenase metabolizing alcohol to acetaldehyde, and aldehyde dehydrogenase 
converting acetaldehyde into acetic acid. Alcohol intoxication can occur more readily, even 
with less ethanol consumption, in persons lacking these enzymes, as in some Asian 
populations. Symptoms of ethanol intoxication are correlated to blood alcohol levels. 
Alcohol dependency involves a need to increase the amount of alcohol to achieve a past 
same effect and unsuccessful efforts to diminish use despite the knowledge of its deleterious 
effects. Social and occupational dysfunction is common. 
3.4.1.1 Alcohol intoxication 
Toxicity occurs within hours of drinking. At levels of 0.05 mg/dl, disinhibition and 
disturbed judgment becomes evident in non-addicted persons. Motor function disruption is 
apparent at concentrations above 0.1%. Confusion and encephalopathy occurs near 0.3%, 
while coma is often observered at concentrations above 0.4%. Death is most commonly 
secondary to respiratory inhibition29. Signs of intoxication include slurring of speech, motor 
clumsiness, nystagmus, impaired cognition with delirium, and respiratory depression26. In 
such circumstances, it may be necessary to rule out intracranial hemorrhage, by obtaining a 
brain imaging scan of the head.  
3.4.1.2 Alcohol withdrawal 
In ethanol addicted individuals, a withdrawal syndrome can occur within half a day from 
the last drink or lower alcohol ingestion depending on the amount consumed, other 
substances used, patient’s tolerance, hepatic status, and enzymatic activity. Withdrawal is 
associated with autonomic hyperactivity of vital signs, tremors, sweating, anxiety, 
decreased sleep, and/or perceptual disturbance (visual or tactile hallucinations). Grand-mal 
seizures can develop in up to 3% of this population29.  
Delirium Tremens (DTs) is a life threatening degree of withdrawal. It develops, within 
days to two weeks in addicted individuals after abrupt abstinence or reduced ethanol 
consumption. The DTs is characterized by severe withdrawal symptoms, seizures, fever, 
and a delirium27.  
www.intechopen.com
 
Acute Encephalopathies and Psychiatry 
 
123 
Thiamine deficiency while metabolizing glucose without vitamin B1 can lead to a 
Wernicke Korsakoff syndrome. Wernickes is an acute, sometimes reversible condition, 
secondary to thiamine deficiency leading to bleeding in the mammillary bodies and 
related areas. It is characterized by delirium, ataxia, and ophthalmoplegia. Korsakoff is a 
related disorder presenting with confusion and confabulation. Both can result in a 
residual dementia. 
3.4.2 Encephalopathy related to substance use 
3.4.2.1 Cannabis 
The effects of marijuana usually lasts for up to three hours; yet, its metabolite, 
tetrahydrocannabinol, can accumulate in adipose tissue, lasting for a much longer duration. 
This natural substance may cause a delirium30. Chronic use can lead to respiratory epithelial 
damage, increased risk of infections, autonomic hyperactivity, cognitive deficits, and 
teratogenicity 31. Synthetic marijuana is sometimes more common and cheaper than natural 
cannabis. It may be preferred by those who are monitored for drug abuse intake since it is 
not detected by regular urine drug screens. 
3.4.2.2 Stimulants 
Cocaine: Several fatal cocaine-induced agitated encephalopathy cases have been reported32. 
Cocaine-associated delirium usually presents with hyperthermia, bizarre behavior, and 
delirium. It may herald cardiovascular collapse and death.  
3.4.2.3 Hallucinogens 
Ecstasy (3,4 methylenedioxymethamphetamine) or MDMA: Several post-ecstasy 
ingestion reports of delirium have been described in the literature 33. This drug is 
thought to combine the effects of lysergic acid diethylamide (LSD) and amphetamines, 
leading to higher serotonin and dopamine levels. Intake of this substance leads initially 
to elevation in mood and increased sociability; while in individuals naïve to the drug, it 
can lead to anorexia, sweating, and elevated vital signs. Psychosis, confusion, and 
disorganization are sometimes documented34. This is mediated by hyperthermic effects 
of the drug, resulting in electrolyte imbalance with neurotoxicity that can precipitate 
seizures. 
Gamma-hydroxybutyrate (GHB): This substance is a naturally occurring analog of gamma-
aminobutyric acid (GABA). There are two other precursor drugs that are inactive unless 
metabolized into GHB within the body. Cross tolerance between ethanol and these 
substances do exist35. 
Intoxication with these short-acting agents can leads to euphoria, disinhibition, respiratory 
depression, and significant central nervous system depression. Combativeness is observed 
during such intoxications. Hypotension and/or bradycardia are documented. The toxicity 
usually resolves within a few hours due to the short half-life of the drug35. With medical 
intervention, fatalities are uncommon. 
Withdrawal has been reported after drug discontinuation in individuals abusing GHB for 
long periods. High doses of benzodiazepines are required to treat withdrawal tremors, 
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seizures, hallucinations, delusions, autonomic hyperactivity, and delirium36. Deaths are 
reported10. Diagnosis is difficult since GHB is non-detectable by routine drug screening 
and even with special urine testing it is usually no longer detected 12 hours after 
ingestion10.  
3.4.2.4 Opiates 
This group of medication has been linked to hypoactive delirium37. Sedation, sleep 
disturbances, slowed mentation, and inattention are frequent signs. The mechanism is 
probably multifactorial; yet, anticholinergic effects of these agents might be prominent. 
Methadone has unpredictable pharmacokinetics and varies from one person to another. 
Naltrexone, a long-acting opioid antagonist, has frequently been used for rapid 
detoxification from opiates and blunts the pleasurable effects of opiates. In rare instances, 
naltrexone leads to delirium38. Disorientation, psychosis, and poor attention or 
concentration are documented and followed by evidence for withdrawal that includes 
mydriasis, diarrhea, lacrimation, muscle aches, abdominal discomfort, piloerection, and 
yawning. 
Dextromethorphan is a frequently used antitussive drug that is a dextrorotatory isomer of 
codeine. When degraded by the liver, it forms a phencyclidine (PCP)-like substance, 
dextrorphan39. This over-the-counter preparation is frequently abused, and in high dosage 
can lead to a delirium with euphoria, autonomic hyperactivity, psychosis, agitation, and 
violent behavior. Ataxia, dysarthria, and seizures have also been reported. Elderly people 
are more prone to these ill effects, even at conventional doses40.  
3.4.2.5 Others 
Nicotine Withdrawal: Sudden discontinuation of smoking tobacco leads to bradycardia, 
agitation, and irritability. On very rare occasions, a delirium or psychosis is documented 
after discontinuation of nicotine41,42. 
Ketamine: This agent is related to phencyclidine and is utilized as an anesthetic due to its 
analgesic and amnestic effects. Due to its tendency to cause psychoses with illusions, 
depersonalization, and even delirium, it is not commonly prescribed, but remains in a 
research status. Such encephalopathies are thought to be more frequent among females 
using rapid and/or high drug dosage43. 
4. Capacity and competency of the patient to make a decision 
In a medical setting it is challenging when an ill patient decides not to proceed with an 
investigation, procedure, and/or treatment. Yet, imposing a decision on someone is only 
legitimate in certain situations. Forced interventions against an individual’s stated wishes 
can only be done if the patient is legally declared not competent or found not to be clinically 
of decisional capacity.  
Competency can only be determined in a judicial setting by a court order. The judge 
permanently appoints a medical guardian to make all future medical decisions. Arranging 
this may take several days to weeks, rending it unpractical in emergencies. 
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A medical team might consult with a psychiatrist for a bedside evaluation to determine 
whether a patient has the “decisional capacity” to make their own medical decisions. 
The capacity to make a decision must be specific to a particular procedure or plan at a 
specific time. Unless the individual is overtly delirious or unable to understand their 
situation, a thorough evaluation is necessary. Decisional capacity can vary between 
being present or absent quickly over time or vacillate back and forth. The psychiatrist 
must collaborate with the treating physician to understand the necessity of a procedure 
and consequences if it is not done in order to communicate this to the patient during the 
assessment. 
There are several issues that must be documented as to reasons why a person is determined 
to be non-decisional at specific time44. They must understand information about their 
disease, its prognosis, and the suggested procedure. These individuals must understand 
their own decision and the reasoning behind it. Patients should comprehend alternatives 
and be able to choose between them. It is helpful to ask all evaluated persons to repeat back 
their understandings. To be decisional, the patient must demonstrate acceptance of the 
pathology diagnosed, the advantages and disadvantages of the proposed intervention, and 
the pros and cons of refusing the medical recommendations. A limited understanding may 
render people as non-decisional. For example, someone in a coma is never decisional. The 
individuals involved should be able to clearly communicate their wishes. Communication 
usually is in the form of speaking or writing, and it must always reflect good understanding 
of the clinical circumstances. If the patient’s wishes are inconsistent or unclear, this infers a 
lack of decisional capacity. 
All decisional patients are able to coherently clarify their decision and reasoning. Once 
found to be non-decisional, relatives or medical surrogates are called upon for making 
medical decisions. In overt emergencies, physicians may become the surrogate when family 
or guardians are not available; documented collaboration with colleagues and a hospital 
medical ethics committee consultation is helpful and provides some legal protection. In non-
emergent cases, seek permission from a court to obtain guardianship for the non-decisional 
patient when surrogate decision makers are not available. 
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